Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA CARE Ctr
-
Los Angeles, California, United States, 90033
- USC School of Medicine / Norris Cancer Hosp
-
San Francisco, California, United States, 94118
- Children's Hosp of San Francisco
-
San Francisco, California, United States, 94118
- Pacific Presbyterian
-
Sherman Oaks, California, United States, 91403
- Gottlieb Med Group
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- AIDS Research Consortium of Atlanta
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush Presbyterian - Saint Luke's Med Ctr / Rush Med Coll
-
-
New York
-
New York, New York, United States, 10025
- Saint Luke's - Roosevelt Hosp Ctr
-
New York, New York, United States, 10016
- Dr Douglas Dieterich
-
New York, New York, United States, 10003
- Cabrini Med Ctr
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Univ of Pennsylvania
-
-
Texas
-
Dallas, Texas, United States, 75235
- Univ of Texas Southwestern Med Ctr of Dallas
-
Houston, Texas, United States, 77030
- Methodist Hosp
-
-
Virginia
-
Annandale, Virginia, United States, 22203
- Infectious Disease Physicians Inc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patient must have the following:
- AIDS as defined by CDC criteria.
- Retinitis as diagnosed by the study ophthalmologist.
- Performance status 0, 1, or 2.
- Ability to give informed consent and suitability of intravenous access for scheduled blood tests.
- Patient may have Kaposi's sarcoma or basal skin cancer.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Active acute infection requiring treatment.
- Corneal, lens, or vitreal opacification which precludes examination of the fundi, or evidence of retinopathy.
- Malignancy other than Kaposi's sarcoma (KS) or basal skin cancer.
Patients with the following are excluded:
- Active acute infection requiring treatment.
- Corneal, lens, or vitreal opacification which precludes examination of the fundi, or evidence of retinopathy.
- Malignancy other than Kaposi's sarcoma (KS) or basal skin cancer.
Prior Medication:
Excluded:
- Granulocyte macrophage colony-stimulating factor (GM-CSF).
- Colony stimulating factor.
- Interleukin 3.
- Excluded within 7 days of study entry:
- Zidovudine (AZT).
- Trimethoprim / sulfamethoxazole (TMP / SMX).
- Pyrimethamine.
- Excluded within 30 days of study entry:
- Biologic response modifiers.
- Cytotoxic agents.
- Investigational agents.
Prior Treatment:
Excluded:
- Radiation therapy.
Required within 1 week of study entry:
- One or more doses of ganciclovir.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Virus Diseases
- Eye Diseases
- Retinal Diseases
- DNA Virus Infections
- Herpesviridae Infections
- Eye Infections
- Eye Infections, Viral
- Cytomegalovirus Infections
- Infections
- Retinitis
- Cytomegalovirus Retinitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Immunologic Factors
- Sargramostim
- Ganciclovir
- Ganciclovir triphosphate
Other Study ID Numbers
Other Study ID Numbers
- 005A
- C88-059
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.